143 related articles for article (PubMed ID: 26566216)
1. C-Reactive Protein Level Is an Indicator of the Aggressiveness of Advanced Pancreatic Cancer.
Mitsunaga S; Ikeda M; Shimizu S; Ohno I; Takahashi H; Okuyama H; Ueno H; Morizane C; Kondo S; Sakamoto Y; Okusaka T; Ochiai A
Pancreas; 2016 Jan; 45(1):110-6. PubMed ID: 26566216
[TBL] [Abstract][Full Text] [Related]
2. A prognostic model to predict clinical outcomes with first-line gemcitabine-based chemotherapy in advanced pancreatic cancer.
Yi JH; Lee J; Park SH; Lee KT; Lee JK; Lee KH; Choi DW; Choi SH; Heo JS; Lim DH; Park YS; Lim HY; Kang WK; Park K; Park JO
Oncology; 2011; 80(3-4):175-80. PubMed ID: 21701231
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors and prognostic index for chemonaïve and gemcitabine-refractory patients with advanced pancreatic cancer.
Maréchal R; Demols A; Gay F; De Maertelaere V; Arvanitaki M; Hendlisz A; Van Laethem JL
Oncology; 2007; 73(1-2):41-51. PubMed ID: 18334830
[TBL] [Abstract][Full Text] [Related]
4. Practical prognostic index for survival in patients with unresectable pancreatic cancer treated with gemcitabine or S-1.
Kurihara T; Kogo M; Ishii M; Yoneyama K; Kitamura K; Shimada K; Shimizu S; Yoshida H; Kiuchi Y
Hepatogastroenterology; 2015; 62(138):478-84. PubMed ID: 25916086
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors in patients with gemcitabine-refractory pancreatic cancer.
Nakachi K; Furuse J; Ishii H; Suzuki E; Yoshino M
Jpn J Clin Oncol; 2007 Feb; 37(2):114-20. PubMed ID: 17272317
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer.
Mitsunaga S; Ikeda M; Shimizu S; Ohno I; Furuse J; Inagaki M; Higashi S; Kato H; Terao K; Ochiai A
Br J Cancer; 2013 May; 108(10):2063-9. PubMed ID: 23591198
[TBL] [Abstract][Full Text] [Related]
7. Practical prognostic index for patients with metastatic pancreatic cancer treated with gemcitabine.
Sawaki A; Kanemitsu Y; Mizuno N; Takahashi K; Nakamura T; Ioka T; Tanaka S; Nakaizumi A; Salem AA; Ueda R; Yamao K
J Gastroenterol Hepatol; 2008 Aug; 23(8 Pt 1):1292-7. PubMed ID: 18700899
[TBL] [Abstract][Full Text] [Related]
8. Treatment efficacy/safety and prognostic factors in patients with advanced biliary tract cancer receiving gemcitabine monotherapy: an analysis of 100 cases.
Suzuki E; Furuse J; Ikeda M; Okusaka T; Nakachi K; Mitsunaga S; Ueno H; Morizane C; Kondo S; Shimizu S; Kojima Y; Hagihara A
Oncology; 2010; 79(1-2):39-45. PubMed ID: 21063134
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of serum CA19-9 in patients with advanced pancreatic cancer receiving gemcitabine based chemotherapy.
An X; Li YH; Lin XB; Wang FH; Feng F; Xu RH; Jiang WQ; He YJ
Ai Zheng; 2009 Mar; 28(3):286-91. PubMed ID: 19619444
[TBL] [Abstract][Full Text] [Related]
10. Ribonucleotide reductase M2 does not predict survival in patients with resectable pancreatic adenocarcinoma.
Xie H; Lin J; Thomas DG; Jiang W; Liu X
Int J Clin Exp Pathol; 2012; 5(4):347-55. PubMed ID: 22670179
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Value of Combined Detection of Serum IL6, YKL-40, and C-reactive Protein in Patients with Unresectable Pancreatic Cancer.
Chen IM; Johansen AZ; Dehlendorff C; Jensen BV; Bojesen SE; Pfeiffer P; Bjerregaard JK; Nielsen SE; Andersen F; Holländer NH; Yilmaz MK; Rasmussen LS; Johansen JS
Cancer Epidemiol Biomarkers Prev; 2020 Jan; 29(1):176-184. PubMed ID: 31685562
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of metallic stents in patients with unresectable pancreatic cancer receiving gemcitabine.
Nakai Y; Isayama H; Kawabe T; Tsujino T; Yoshida H; Sasaki T; Tada M; Arizumi T; Yagioka H; Kogure H; Togawa O; Ito Y; Matsubara S; Hirano K; Sasahira N; Omata M
Pancreas; 2008 Nov; 37(4):405-10. PubMed ID: 18953253
[TBL] [Abstract][Full Text] [Related]
13. Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma.
Maréchal R; Bachet JB; Mackey JR; Dalban C; Demetter P; Graham K; Couvelard A; Svrcek M; Bardier-Dupas A; Hammel P; Sauvanet A; Louvet C; Paye F; Rougier P; Penna C; André T; Dumontet C; Cass CE; Jordheim LP; Matera EL; Closset J; Salmon I; Devière J; Emile JF; Van Laethem JL
Gastroenterology; 2012 Sep; 143(3):664-674.e6. PubMed ID: 22705007
[TBL] [Abstract][Full Text] [Related]
14. The Impact of SMAD4 Loss on Outcome in Patients with Advanced Pancreatic Cancer Treated with Systemic Chemotherapy.
Ormanns S; Haas M; Remold A; Kruger S; Holdenrieder S; Kirchner T; Heinemann V; Boeck S
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28534865
[TBL] [Abstract][Full Text] [Related]
15. Real-world Outcomes Among Patients Treated With Gemcitabine-based Therapy Post-FOLFIRINOX Failure in Advanced Pancreatic Cancer.
Tsang ES; Spratlin J; Cheung WY; Kim CA; Kong S; Xu Y; Gill S
Am J Clin Oncol; 2019 Dec; 42(12):903-908. PubMed ID: 31693510
[TBL] [Abstract][Full Text] [Related]
16. First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer.
Vaccaro V; Bria E; Sperduti I; Gelibter A; Moscetti L; Mansueto G; Ruggeri EM; Gamucci T; Cognetti F; Milella M
World J Gastroenterol; 2013 Jul; 19(28):4511-9. PubMed ID: 23901226
[TBL] [Abstract][Full Text] [Related]
17. Do recurrent and metastatic pancreatic cancer patients have the same outcomes with gemcitabine treatment?
Hashimoto K; Ueno H; Ikeda M; Kojima Y; Hagihara A; Kondo S; Morizane C; Okusaka T
Oncology; 2009; 77(3-4):217-23. PubMed ID: 19729980
[TBL] [Abstract][Full Text] [Related]
18. Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients.
Szkandera J; Stotz M; Absenger G; Stojakovic T; Samonigg H; Kornprat P; Schaberl-Moser R; Alzoughbi W; Lackner C; Ress AL; Seggewies FS; Gerger A; Hoefler G; Pichler M
Br J Cancer; 2014 Jan; 110(1):183-8. PubMed ID: 24201751
[TBL] [Abstract][Full Text] [Related]
19. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA
BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161
[TBL] [Abstract][Full Text] [Related]
20. Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab-paclitaxel or FOLFIRINOX: A post-hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study).
Shibuki T; Mizuta T; Shimokawa M; Koga F; Ueda Y; Nakazawa J; Komori A; Otsu S; Arima S; Fukahori M; Makiyama A; Taguchi H; Honda T; Mitsugi K; Nio K; Ide Y; Ureshino N; Shirakawa T; Otsuka T
BMC Cancer; 2022 Jan; 22(1):19. PubMed ID: 34980029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]